125 related articles for article (PubMed ID: 28581473)
1. Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
Balduzzi A
Bone Marrow Transplant; 2017 Jul; 52(7):952-954. PubMed ID: 28581473
[No Abstract] [Full Text] [Related]
2. Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
Pan X; Nariai N; Fukuhara N; Saito S; Sato Y; Katsuoka F; Kojima K; Kuroki Y; Danjoh I; Saito R; Hasegawa S; Okitsu Y; Kondo A; Onishi Y; Nagami F; Kiyomoto H; Hozawa A; Fuse N; Nagasaki M; Shimizu R; Yasuda J; Harigae H; Yamamoto M
Br J Haematol; 2017 Jan; 176(2):318-321. PubMed ID: 26822323
[No Abstract] [Full Text] [Related]
3. [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():565-9. PubMed ID: 30714704
[No Abstract] [Full Text] [Related]
4. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing for measuring minimal residual disease in AML.
Walter RB; Appelbaum FR
Nat Rev Clin Oncol; 2018 Aug; 15(8):473-474. PubMed ID: 29795270
[No Abstract] [Full Text] [Related]
6. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
Nishihori T; Song J; Shain KH
Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
[TBL] [Abstract][Full Text] [Related]
8. Standardisation of minimal residual disease in multiple myeloma.
Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
[TBL] [Abstract][Full Text] [Related]
9. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
10. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
11. Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease.
Bartram J; Mountjoy E; Brooks T; Hancock J; Williamson H; Wright G; Moppett J; Goulden N; Hubank M
J Mol Diagn; 2016 Jul; 18(4):494-506. PubMed ID: 27183494
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.
Bibault JE; Figeac M; Hélevaut N; Rodriguez C; Quief S; Sebda S; Renneville A; Nibourel O; Rousselot P; Gruson B; Dombret H; Castaigne S; Preudhomme C
Oncotarget; 2015 Sep; 6(26):22812-21. PubMed ID: 26078355
[TBL] [Abstract][Full Text] [Related]
13. There is nothing minimal about residual disease.
Radich JP
Blood; 2018 Mar; 131(12):1269-1270. PubMed ID: 29567755
[No Abstract] [Full Text] [Related]
14. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Martinez-Lopez J; Sanchez-Vega B; Barrio S; Cuenca I; Ruiz-Heredia Y; Alonso R; Rapado I; Marin C; Cedena MT; Paiva B; Puig N; Mateos MV; Ayala R; Hernández MT; Jimenez C; Rosiñol L; Martínez R; Teruel AI; Gutiérrez N; Martin-Ramos ML; Oriol A; Bargay J; Bladé J; San-Miguel J; Garcia-Sanz R; Lahuerta JJ
Leukemia; 2017 Jun; 31(6):1446-1449. PubMed ID: 28210002
[No Abstract] [Full Text] [Related]
15. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
16. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
17. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease testing after stem cell transplantation for multiple myeloma.
Sherrod AM; Hari P; Mosse CA; Walker RC; Cornell RF
Bone Marrow Transplant; 2016 Jan; 51(1):2-12. PubMed ID: 26191950
[TBL] [Abstract][Full Text] [Related]
19. High-throughput sequencing detects signs of cancer recurrence.
Printz C
Cancer; 2012 Sep; 118(17):4097. PubMed ID: 22907702
[No Abstract] [Full Text] [Related]
20. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
Chase ML; Armand P
Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
